Abstract
Seasonal influenza imposes a significant health and economic burden in South Africa, particularly in populations vulnerable to severe consequences of influenza. This study assesses the cost-effectiveness of South Africa's seasonal influenza vaccination strategy, which involves vaccinating vulnerable populations with trivalent inactivated influenza vaccine (TIV) during routine facility visits. Vulnerable populations included in our analysis are persons aged≥65years; pregnant women; persons living with HIV/AIDS (PLWHA), persons of any age with underlying medical conditions (UMC) and children aged 6-59months. We employed the World Health Organisation's (WHO) Cost Effectiveness Tool for Seasonal Influenza Vaccination (CETSIV), a decision tree model, to evaluate the 2018 seasonal influenza vaccination campaign from a public healthcare provider and societal perspective. CETSIV was populated with existing country-specific demographic, epidemiologic and coverage data to estimate incremental cost-effectiveness ratios (ICERs) by comparing costs and benefits of the influenza vaccination programme to no vaccination. The highest number of clinical events (influenza cases, outpatient visits, hospitalisation and deaths) were averted in PLWHA and persons with other UMCs. Using a cost-effectiveness threshold of US$ 3400 per quality-adjusted life year (QALY), our findings suggest that the vaccination programme is cost-effective for all vulnerable populations except for children aged 6-59months. ICERs ranged from~US$ 1 750 /QALY in PLWHA to~US$ 7500/QALY in children. In probabilistic sensitivity analyses, the vaccination programme was cost-effective in pregnant women, PLWHA, persons with UMCs and persons aged≥65years in>80% of simulations. These findings were robust to changes in many model inputs but were most sensitive to uncertainty in estimates of influenza-associated illness burden. South Africa's seasonal influenza vaccination strategy of opportunistically targeting vulnerable populations during routine visits is cost-effective. A budget impact analysis will be useful for supporting future expansions of the programme.
Full Text
Topics from this Paper
Persons Living With HIV/AIDS
Underlying Medical Conditions
Seasonal Influenza Vaccination
Routine Visits
Seasonal Influenza Vaccination Programme
+ Show 5 more
Create a personalized feed of these topics
Get StartedTalk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Similar Papers
Annals of Emergency Medicine
Sep 1, 2010
American Journal of Transplantation
Dec 1, 2014
Clinical Microbiology and Infection
May 1, 2023
Annals of Emergency Medicine
Sep 1, 2010
Vaccine
Oct 1, 2022
Indian Journal of Endocrinology and Metabolism
Jan 1, 2012
Clinical Drug Investigation
Feb 1, 2012
BMC Medicine
Sep 8, 2017
Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
Oct 10, 2021
Human Vaccines & Immunotherapeutics
Jul 2, 2016
Social Science & Medicine
Mar 1, 2003
American Journal of Transplantation
Oct 1, 2015
American Journal of Obstetrics and Gynecology
Dec 1, 2009
BMC Medicine
Apr 14, 2020
BMC Medicine
Apr 14, 2020
Vaccine
Vaccine
Nov 1, 2023
Vaccine
Nov 1, 2023
Vaccine
Nov 1, 2023
Vaccine
Nov 1, 2023
Vaccine
Nov 1, 2023
Vaccine
Nov 1, 2023
Vaccine
Nov 1, 2023
Vaccine
Nov 1, 2023
Vaccine
Nov 1, 2023